Immunotherapy represents a significant paradigm shift in the treatment of various malignancies. By harnessing the power of the immune system, it has the potential to offer durable responses and improved survival outcomes. This article provides an overview of the basic principles of immunotherapy, its applications, and the management of associated adverse events.
Immunotherapy works by stimulating or restoring the immune system's ability to fight cancer. This is achieved through several mechanisms, including immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Understanding these modalities is crucial to guide treatment decisions and manage potential toxicities.
Immunotherapy has shown efficacy in various cancers, including melanoma, lung cancer, and hematological malignancies. For instance, checkpoint inhibitors such as pembrolizumab and nivolumab have revolutionized the treatment of advanced melanoma and non-small cell lung cancer. Additionally, CAR-T cell therapies have provided remarkable outcomes in refractory hematological malignancies.
While immunotherapy offers significant benefits, it can also lead to immune-related adverse events (irAEs). These can affect any organ system and often resemble autoimmune or inflammatory conditions. Early recognition and appropriate management of irAEs are critical to minimize morbidity and mortality. This includes the use of corticosteroids or other immunosuppressants, and in severe cases, discontinuation of therapy.
Research is ongoing to expand the use of immunotherapy to other cancers and to optimize its efficacy. This includes combination strategies, biomarker development, and overcoming resistance mechanisms. Staying abreast of these advancements is vital for physicians to provide the best care for their patients.
Immunotherapy has undoubtedly transformed the landscape of oncology. As physicians, understanding the principles of immunotherapy, its applications, and management of adverse events is essential to maximize patient outcomes. Continued education and research in this field will further refine our therapeutic arsenal against cancer.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation